Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer
- PMID: 31695780
- PMCID: PMC6831307
- DOI: 10.7150/thno.38081
Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer
Abstract
Purpose: Colitis-associated colorectal cancer (CAC) poses substantial challenges for effective treatment. Currently, there is a considerable need for the development of orally bioavailable dosage forms that enable the safe and effective delivery of therapeutic drugs to local diseased lesions in the gastrointestinal tract. Experimental Design: In this study, we developed orally deliverable nanotherapeutics for the synergistic treatment of inflammatory bowel diseases (IBDs) and CAC. Water-insoluble curcumin (CUR) and 7-ethyl-10-hydroxycamptothecin (SN38), which served as anti-inflammatory and cytotoxic agents, respectively, were chemically engineered into hydrophilic mucoadhesive chitosan for the generation of chitosan-drug amphiphiles. Results: The resulting amphiphilic constructs formed core-shell nanostructures in aqueous solutions and were orally administered for in vivo therapeutic studies. Using a preclinical CAC mouse model, we showed that the orally delivered nanotherapeutics locally accumulated in inflamed intestinal regions and tumor tissues. Furthermore, the therapeutic synergy of the combined nanotherapeutics in CAC mice was evaluated. Compared with their individual drug forms, combined CUR and SN38 nanoparticles yielded synergistic effects to alleviate intestinal inflammation and protect mice from ulcerative colitis. Notably, the combinatorial therapy demonstrated a remarkable tumor shrinkage with only ~6% of the total tumors exceeding 4 mm in diameter, whereas ~35% of tumors were observed to exceed a diameter of 4 mm in the saline-treated CAC mice. These data suggest a new and reliable approach for improving the treatment of IBD and CAC. Conclusions: Our results showed that bioadhesive chitosan materials can be used to produce colloidal-stable nanotherapeutics that are suitable for oral delivery. Both nanotherapeutics exhibited substantial accumulation in inflamed intestinal regions and tumor tissues and showed good synergy for treating CAC, warranting further clinical translation.
Keywords: anti-inflammation; colitis-associated colorectal cancer; cytotoxic nanoparticle; oral delivery; self-assembly.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6831307/bin/thnov09p7458g007.gif)
Similar articles
-
Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora.Phytomedicine. 2022 Jul 20;102:154217. doi: 10.1016/j.phymed.2022.154217. Epub 2022 May 27. Phytomedicine. 2022. PMID: 35660350
-
Vitexin prevents colitis-associated carcinogenesis in mice through regulating macrophage polarization.Phytomedicine. 2021 Mar;83:153489. doi: 10.1016/j.phymed.2021.153489. Epub 2021 Jan 30. Phytomedicine. 2021. PMID: 33571919
-
Murine Model for Colitis-Associated Cancer of the Colon.Methods Mol Biol. 2016;1438:245-54. doi: 10.1007/978-1-4939-3661-8_14. Methods Mol Biol. 2016. PMID: 27150094 Free PMC article. Review.
-
Expression of the novel adipokine C1qTNF-related protein 4 (CTRP4) suppresses colitis and colitis-associated colorectal cancer in mice.Cell Mol Immunol. 2016 Sep;13(5):688-99. doi: 10.1038/cmi.2016.16. Epub 2016 Apr 18. Cell Mol Immunol. 2016. PMID: 27086950 Free PMC article.
-
Colitis-associated neoplasia: molecular basis and clinical translation.Cell Mol Life Sci. 2014 Sep;71(18):3523-35. doi: 10.1007/s00018-014-1636-x. Epub 2014 May 15. Cell Mol Life Sci. 2014. PMID: 24830703 Free PMC article. Review.
Cited by
-
Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Bioact Mater. 2024 Mar 20;36:376-412. doi: 10.1016/j.bioactmat.2024.03.003. eCollection 2024 Jun. Bioact Mater. 2024. PMID: 38544737 Free PMC article. Review.
-
Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment.J Nanobiotechnology. 2023 Sep 23;21(1):344. doi: 10.1186/s12951-023-02097-6. J Nanobiotechnology. 2023. PMID: 37741962 Free PMC article.
-
Momordica charantia-Derived Extracellular Vesicles Provide Antioxidant Protection in Ulcerative Colitis.Molecules. 2023 Aug 22;28(17):6182. doi: 10.3390/molecules28176182. Molecules. 2023. PMID: 37687011 Free PMC article.
-
Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.Int J Mol Sci. 2023 Apr 27;24(9):7922. doi: 10.3390/ijms24097922. Int J Mol Sci. 2023. PMID: 37175627 Free PMC article. Review.
-
Catechins: Protective mechanism of antioxidant stress in atherosclerosis.Front Pharmacol. 2023 Mar 24;14:1144878. doi: 10.3389/fphar.2023.1144878. eCollection 2023. Front Pharmacol. 2023. PMID: 37033663 Free PMC article. Review.
References
-
- Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B. et al. Colorectal cancer. Lancet. 2010;375:1030–47. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the yin-yang interplay between inflammation and cancer. Oncogene. 2010;29:3313–23. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical